Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azstarys Efficacy and Duration in Adult ADHD
NCT06000501Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of serdexmethylphenidate + dexmethylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by NYU Langone Health. Started Nov 2023; status: completed.
02
Drugs
serdexmethylphenidate + dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06000501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06000501.